References
Takagi, H., Tominaga, Y., Tanaka, Y., Uchida, K., Orihara, A., Yamada, N., Kawai, M., Hayashi, S., Taira, N., Kano, T.: Total parathyroidectomy with forearm autograft for secondary hyperparathyroidism in chronic renal failure. Ann. Surg. 208: 639–644, 1988
Felsenfeld, A.J., Harrelson, J.M., Gutman, R.A., Wells, S.A. Jr, Drezner, M.K.: Osteomalacia after parathyroidectomy in patients with uremia. Ann. Intern. Med. 96: 34–39, 1982
Andress, D.L., Ott, S.M., Maloney, N.A., Sherrard, D.J.: Effect of parathyroidectomy on bone aluminum accumulation in chronic renal failure. N. Engl. J. Med. 312: 468–473, 1985
Norris, K.C., Crooks, P.W., Nebeker, H.G., Hercz, G., Milliner, D.S., Gerszi, K., Slatopolsky E., Andress, D.L., Sherrard, D.J., Coburn, J.W.: Clinical and laboratory features of aluminum-related bone disease: Differences between sporadic and “epidemic” forms of the syndrome. Am. J. Kid. Dis. 6: 342–347, 1985
Berland, Y., Charhon, S., Olmer, M., Meunier, P.: Changes following parathyroidectomy in hemodialyzed patients. Miner Electr Metab. 9: 176–177, 1983
Cohen Solal ME, Sebert JL, Boudailliez B, Garabedian M, A. Non aluminic adynamic bone disease in non dialyzed uremic patients. A new type of osteopathy due to overtreatment? Bone 13(1): 1–5, 1992
Fournier A, Moriniere P, Cohen Solal ME, Boudailliez JM, Achard JM, Marie A, Sebert JL. Adynamic bone disease in uremia: May it be idiopathic? Is it an actual disease? Nephron 58: 1–12, 1991
Lieberherr, M., Grosse, B., Cournot-Witmer, G., Hermann-Erlee, M.P.M., Balsan, S.: Aluminum action on mouse bone cell metabolism and response to PTH and 1,25 (OH)2D3. Kidney Int. 31: 736–743, 1987
Vukicevic, S., Stavljenic, A: Aluminum accumulates on inactive bone surfaces after parathyroidectomy in uremic rats. Horm. Metabol. Res. 21: 15–17, 1989
Effects of aluminum on the parathyroid hormone receptors of bone and kidney. Kidney Int., 37: 72–78, 1990
Hercz G, Peri Y, Manuel A, Saiphoo C, Goodman WG, Segre GV, Sherrard DJ. Aplastic osteodystrophy without aluminum in dialysis patients (abstract) Kidney Int. 37: 449, 1990
Dunlay, R., Rodriguez, M., Felsenfeld, A., Llach, F.: Parathyroid function in aplastic bone disease without aluminum overload (abstract). Kidney Int. 37: 294, 1900
Andress, D.L., Sherrard, D.J.: The osteodystrophy of chronic renal failure. In: Diseases of the kidney, eds. Schrier, R.W., Gottschalk, C.W, Boston, Little, Brown and Co., pp2759–2788, 1992
Malluche, H.H., Faugere, M-.C.: Effects of 1,25(OH)2D3 administration on bone in patients with renal failure. Kidney Int. 38: S-48–S-53, 1990
Piraino B, Chen T, Cooperstein L, Segre G, Puschett J: Fractures and vertebral bone mineral density in patients with renal osteodystrophy. Clin Nephrol 30: 57–62, 1988
Torres, A., Lorenzo, V., Gonzalez-Posada, J.M.: Comparison of histomorphometry and computerized tomography of the spine in quantitating trabecular bone in renal osteodystrophy. Nephron 44: 282–287, 1986
Malluche, H.H., Faugere, M-.C.: Renal bone disease 1990: An unmet challenge for the nephrologist. Kidney Int. 193–211, 1990
Ito M, Hayashi K, Ito M: Veterbral density distribution pattern: CT classification of patients undergoing maintenance hemodialysis. Radiology 180: 253–257, 1991
Rasmussen JN, Mosekilde L: Local differences in mineral content in vertebral trabecular bone measured by dual-energy computed tomography. Acta Radiol 30: 369–371, 1989
Marumo F, Sakurai K, Sato N, Shimada H, Iwanami S, Uchida H. Influence of long-term hemodialysis on bone mineral content as estimated by computed tomography. In: Nose Y, Kjellstrand C and Ivanovich P, eds. Progress in Artificial Organs, Cleveland, ISAO Press: 192–196, 1986
Sakurai K, Marumo F, Iwanami S, Uchida H, Matsubayashi T. Quantitative computed tomographic evaluation of femoral bone mineral content in renal osteodystrophy compared with radial photon absorptiometry. Invest Radiol 24: 375–382, 1989
Baker, L.R.I., Abrams, S.M.L., Roe, C.J., Faugere, M-.C., Fanti, P., Subayti, Y., Malluche, H.H.: 1,25(OH)2D3 administration in moderate renal failure: A prospective duble-blind trial. Kidney Int. 35: 661–669, 1989
Tsukamoto Y, Nomura Y, Marumo F: Pharmacological parathyroidectomy by oral 1,25(OH)2D2 pulse therapy. Nephron 51: 130–131, 1989
Tsukamoto Y, Nomura Y, Takahashi Takagi Y, Yoshida A, Nagaoka T, Togashi K,: Kikawada R, Marumo F: The ‘oral 1,25-dihydroxyvitamin D3 pulse therapy’ in hemodialysis patients with severe secondary hyperparathyroidism. Nephron 57: 23–28, 1991
Moriya, R., Tsukamoto, Y., Nomura, Y., Sato, N., Sakurai, K.: Relatively high PTH level is required to maintain bone formation in hemodialyzed uremic patients: Effect of PTH on bone mineral content. Bone Miner 17(suppl. 1): 208, 1992
Hodsman, A.B., Wong, E.G.C., Sherrard, D.J., Brickman, A.S., Lee, D.B.NM., Singer, F.R., Norman, A.W., Coburn, J.W.: Preliminary trials with 24,25-dihydroxyvitamin D3 in dialysis osteomalacia. Am. J. Med. 74: 407–414, 1983
Dunstan, C.R., Hills, E., Norman, A.W., Bishop, J.E., Mayer, E., Wong, S.Y.P., Eade, Y., Johnson, J.R., George, C.R.P., Collett, P., Kalowski, S. Wyndham, R.N., Lawrence, J.R., Alfrey, A.C., Evans, R.A.: Treatment of hemodialysis bone disease with 24,25-(OH)2D3 and 1,25-(OH)2D3 alone or in combination. Miner Electr Metab 11: 358–368, 1985
Moscovici, A., Rubinger, D., Popovtzer, M.M.: Long-term effect of combined 1,25(OH)2D3 and 24,25(OH)2D3 therapy on uremic osteodystrophy. J. Amer. Soc. Nephrol. 2: 613, 1991 (abstract)
Birkenhager-Frenkel, D.H., Pols, H.A.P., Nigg, A.L., Clermonts, E., Birkenhager, J.C.: 24,25-dihydroxyvitamin D3 appears to favour cortical bone mass in renal disease. Bone Miner 17 (suppl. 1): 114, 1992
Author information
Authors and Affiliations
About this article
Cite this article
Tsukamoto, Y. Vitamin D induced osteopenia-A possibility?. J Bone Miner Metab 11, S71–S74 (1993). https://doi.org/10.1007/BF02383846
Issue Date:
DOI: https://doi.org/10.1007/BF02383846